CRISPR THERAPEUTICS AG — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-6
Book Value Per Share
$21
Free Cash Flow Per Share
$-4
Cash Per Share
$4
Revenue Per Share
$0
OCF Per Share
$-4
Return on Equity
-30.2%
Return on Assets
-25.8%
Return on Invested Capital
-27.2%
Current Ratio
13.32
Quick Ratio
13.32
Asset Turnover
0.00
Days Sales Outstanding
0.00
R&D / Revenue
8114.1%
SBC / Revenue
2065.5%
Capex / Revenue
26.0%
Working Capital
$1.84B
Net Current Asset Value
$1.64B
Invested Capital
$1.92B
OCF / Net Income
0.59
FCF / Net Income
0.59
Accruals Ratio (Sloan)
-10.4%
Net Debt
$-1.98B
Net Debt / EBITDA
3.06
Interest Coverage
—
Cash Coverage
—
Capex Coverage
-377.48
Tangible Common Equity
$1.92B
TCE / Total Assets
84.8%
NOPAT
$-525M
Cash ROIC
-18.0%
WC / Revenue
52323.4%
Capex / D&A
0.05
Reinvestment Rate
2.8%
Total Payout Ratio
—
Asset Growth vs Revenue Growth
91.6%
Revenue 5Y CAGR
37.3%
Book Value 5Y CAGR
2.9%
Stock Price (FY-end)
$52
Market Cap
$4.72B
P/E Ratio
—
P/S Ratio
1343.50
P/B Ratio
2.45
P/TB Ratio
2.45
P/OCF Ratio
—
P/FCF Ratio
—
Enterprise Value
$2.74B
EV / EBITDA
—
EV / Sales
780.58
EV / FCF
—
FCF Yield
-7.3%
Shareholder Yield
-1.5%
Buyback Yield
—
R&D Yield
6.0%
Capex Yield
0.0%
Operating Leverage
—
Graham Number
—
Shares Variation (YoY)
6.6%
Beta (5Y)
1.53
Cost of Equity
12.1%
52W High
$77
52W Low
$31
Trailing Return 1Y
31.0%
Trailing Return 5Y
-69.7%
F-Score (Piotroski)
1.00
Z-Score (Altman)
7.04
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.